Built for investors and grounded in the latest healthcare data, Qsight Alpha consistently outperforms consensus. It offers unparalleled visibility and precise insights into the performance and anticipated revenues of companies in the MedTech sector through monthly and quarterly tracking of manufacturers.
Guidepoint Qsight Alpha is a powerful tool designed specifically for institutional investors, using the largest datasets available to provide near real-time insights into manufacturer and product-level performance.
Qsight Alpha
With Qsight Alpha, investors can confidently navigate the complexities of the MedTech market, leveraging robust data to identify trends and opportunities ahead of the competition. By staying informed and proactive, investors using Qsight Alpha can capitalize on emerging market trends and position themselves strategically for success.
To use Qsight Alpha, simply access the platform to track monthly and quarterly sales data. This allows you to see beyond standard market consensus with greater accuracy. As an indispensable tool for investors, Qsight Alpha provides precise and predictive revenue visibility to make smarter, data-driven investment decisions in these rapidly evolving industries.
How Qsight Alpha Can Maximize Investment Potential
Comprehensive MedTech Alpha Tool
Frequently Asked Questions
About Qsight Alpha
Qsight Alpha provides detailed insights and data tracking for companies in the MedTech and DME sectors.
Qsight Alpha stands out due to its ability to consistently outperform consensus forecasts and its access to comprehensive sales data from over 3,500 U.S. healthcare facilities. It provides unparalleled visibility into the anticipated revenues and performance of MedTech companies.
Qsight Alpha uses comprehensive data intelligence derived from an extensive dataset, including purchasing data from over 3,500 healthcare facilities and 5,000 U.S. Durable Medical Equipment (DME) pharmacy locations.
This platform offers near real-time insights into manufacturer and product-level performance with a mean absolute percentage error of just 1.68% in its projections since 2021. With weekly updates and detailed monthly data going back to 2010, Qsight Alpha provides investors with precise and predictive revenue visibility.
Delivering More Than Just Data
Request a Demo Today
At Guidepoint Qsight, we empower decisions through unmatched, data-driven insights for the aesthetics, MedTech, and therapeutics industries. Send us your contact information today, and we’ll be in touch to discuss your concerns and overall needs. When it comes to data analytics, we’re the experts you can count on.
Lightning Strikes the Peripheral Thrombectomy Market: Examining the Rise of Penumbra and the Impact of Innovative Devices
The peripheral thrombectomy market in the United States has been witnessing significant growth and innovation in recent years. With new devices constantly entering the market, Qsight’s healthcare facilities purchasing data has been monitoring the impact of these new products.
Rapid Ascend: Axonics Gains Ground in the SNM Market Amid F15 Launch and Next-Gen R20 System Arrival
Qsight has been monitoring the Axonics F15 SNM System since its launch in March 2022. Our healthcare facilities dataset shows that Axonics experienced a rapid increase in sales after the launch of this system, as this system offers a recharge-free option that now directly competes with Medtronic’s Interstim X.
Medical Aesthetics Industry Faces Economic Uncertainty: Putting the “Lipstick Effect” to the Test
As 2023 began with lingering economic concerns from 2022 (inflation, rising interest rates, risk of recession, etc.), the aesthetics industry’s hope for continued strong growth may be challenged.
TAVR: A Turbulent Journey Through Pandemic Recovery
With the leader of the TAVR market, Edwards Lifesciences, reporting a small miss in their third quarter earnings report, Guidepoint Qsight analyzed the short term and long-term effects of COVID-19 on the overall U.S. TAVR market.